Kenvue Inc. (KVUE) Stock Analysis
Breakout setup
Consumer Defensive · Household & Personal Products
Hold if already holding. Not a fresh buy at $18.14, but acceptable to hold if already in. Reason: Analyst target reached - limited upside remaining.
Kenvue is a global consumer health company with $15.1B in net sales in fiscal 2025 across three segments: Self Care (Tylenol, Zyrtec, Nicorette), Skin Health and Beauty (Neutrogena, Aveeno), and Essential Health (Listerine, BAND-AID, Johnson's). Products are sold in 165+... Read more
Hold if already holding. Not a fresh buy at $18.14, but acceptable to hold if already in. Reason: Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Maintain position. Not compelling to add more. Score 5.8/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and 8k serious 2.05. Suitability: moderate.
Recent developments
updated 2026-06-14Recent Developments — Kenvue Inc.
Latest news
- NEWS Vest Financial LLC Has $56.02 Million Holdings in Kenvue Inc. $KVUE - MarketBeat — MarketBeat neutral
- NEWS Kenvue Stock: Is Wall Street Bullish or Bearish? - Yahoo Finance — Yahoo Finance neutral
- NEWS RNC Capital Management LLC Sells 1,777,156 Shares of Kenvue Inc. $KVUE - MarketBeat — MarketBeat neutral
- NEWS Oppenheimer & Co. Inc. Sells 124,355 Shares of Kenvue Inc. $KVUE - MarketBeat — MarketBeat neutral
- NEWS Kenvue Inc. $KVUE Position Trimmed by Keybank National Association OH - MarketBeat — MarketBeat neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-02-12Item 5.02HIGHCFO Amit Banati notified company he will step down effective May 12, 2026 to become CEO of another company. No successor named at time of filing; company intends to appoint an interim principal financial officer pending merger with Kimberly-Clark.SEC filing →
- 2026-02-17Item 2.05MEDIUMBoard approved a restructuring initiative on February 17, 2026. Financial details and scope of exit/disposal activities disclosed. No specific charges quantified in available body text.SEC filing →
- 2026-04-15Item 5.02MEDIUMHeather Howlett (current CAO) appointed as interim CFO and CAO effective May 12, 2026, succeeding departing CFO Amit Banati. Monthly stipend of $125,000 added to current compensation. Interim designation in light of pending Kimberly-Clark merger.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $18.14, but acceptable to hold if already in. Reason: Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Maintain position. Not compelling to add more. Target $17.89 (-1.4%), stop $17.38 (−4.4%), A.R:R -0.8:1. Score 5.8/10, moderate confidence.
Take-profit target: $17.89 (-1.4% upside). Target $17.89 (-1.4%), stop $17.38 (−4.4%), A.R:R -0.8:1. Stop-loss: $17.38.
Analyst target reached - limited upside remaining.
Kenvue Inc. trades at a P/E of 21.6 (forward 14.7). TrendMatrix value score: 6.0/10. Verdict: Hold.
18 analysts cover KVUE with a consensus score of 2.7/5. Average price target: $20.
What does Kenvue Inc. do?Kenvue is a global consumer health company with $15.1B in net sales in fiscal 2025 across three segments: Self Care...
Kenvue is a global consumer health company with $15.1B in net sales in fiscal 2025 across three segments: Self Care (Tylenol, Zyrtec, Nicorette), Skin Health and Beauty (Neutrogena, Aveeno), and Essential Health (Listerine, BAND-AID, Johnson's). Products are sold in 165+ countries; the company has a pending merger with Kimberly-Clark announced November 2025.